Clinical trials: Stem Cell Transplant Patients
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
This phase I trial studies the side effects of human lysozyme goat milk in preventing graft versus host disease in patients with blood cancer undergoing a donor stem cell transplant.
- Trial name
- NCT04177004
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Autologous Hematopoietic Stem Cell Transplant
Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.
The goal of this clinical study is to evaluate the safety of cytokine-induced-killer (CIK) cells during early transplant period of autologous hematopoietic stem cell transplant.
- Trial name
- NCT07692607
- Testing
- CIK cells
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- LucasBio
Haematopoietic Stem Cell Transplant, Allogeneic
BANDICOOT: An Adaptive Platform Trial to Improve Health Outcomes After Paediatric Stem Cell Transplant
Background: In children with >120 rare diseases, haematopoietic stem cell transplant (HSCT) provides a medical "reset" for the body, replacing diseased or dysfunctional bone marrow with healthy donor-derived stem cells following…
- Trial name
- BANDICOOT (NCT07679100)
- Testing
- Standard care
- Volunteers
- 10,000 people
- Sponsor
- Murdoch Childrens Research Institute
Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant.
- Conditions
- Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis
- Trial name
- NCT04098445
- Where
- 9 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Relapsed Adult AML, Stem Cell Transplant Complications
Menin-Inhibitor Targeted Maintenance in AML
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML.
- Conditions
- Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
- Trial name
- NCT07563010
- Testing
- Revumenib
- Volunteers
- 146 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Cancer, Caregivers
Psychoeducation for AlloHCT Caregivers
Background: Caregivers of patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for hematological malignancies face significant challenges that can impact their well-being.
- Conditions
- Cancer, Caregivers, Stem Cell Transplant, Psychoeduction
- Trial name
- NCT07116018
- Testing
- Psychoeducation
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- University Health Network, Toronto
Hematopoietic Stem Cell Transplant
Light Therapy to Treat Depression in Pediatric Stem Cell Therapy Recipients
The participants are being asked to be in this clinical trial, a type of research study, because the participants are going to have a hematopoietic stem cell transplant (HSCT) in the near future.
- Trial name
- NCT06496477
- Testing
- Ayo wearable
- Where
- United States
- Sponsor
- St. Jude Children's Research Hospital
Multiple Sclerosis, Autologous Hematopoietic Stem Cell Transplant
ATLG Levels in Autologous HSCT for Multiple Sclerosis
This is a prospective, observational, biological, multicenter study to investigate IR profile, ATLG dynamics, main HSCT and disease outcomes in MS.
- Conditions
- Multiple Sclerosis, Autologous Hematopoietic Stem Cell Transplant, ATLG
- Trial name
- ATLG-MS (NCT07635693)
- Testing
- ATLG administration
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Ciceri Fabio
Sickle Cell Disease, Hematopoetic Stem Cell Transplant
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young…
- Conditions
- Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation
- Trial name
- RUX-HAPLO (NCT07252050)
- Testing
- Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable…
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)
- Trial name
- NCT03613532
- Testing
- Venetoclax, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jacqueline Garcia, MD
Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
The REACT Study: REhabilitation and ACTivity in Allogenic Transplant
A prospective, longitudinal cohort study will be conducted to evaluate the effects of treatment on the physical function of patients undergoing Allogeneic Hematopoeitic Stem Cell Transplant.
- Trial name
- REACT (NCT07581093)
- Volunteers
- 140 people
- Sponsor
- University of Dublin, Trinity College
Stem Cell Transplant, Late Effect
Strength Training as Prevention and Treatment of Late Effects in Long-term Survivors of Pediatric HSCT.
Today the overall survival of childhood cancers has increased to above 85%. This increase is partially caused by treatment with bone marrow transplantation.
- Conditions
- Stem Cell Transplant, Late Effect, Metabolic Syndrome, Cardiovascular Diseases
- Trial name
- STEPS (NCT04922970)
- Testing
- Strength training
- Where
- Denmark
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hematopoietic Stem Cell Transplant
Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing…
- Trial name
- NCT05945121
- Testing
- Cardio-oncology program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Michigan Rogel Cancer Center
Sickle Cell Disease, Stem Cell Transplant Complications
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a…
- Conditions
- Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell Aplasia
- Trial name
- Sickle-AID (NCT03214354)
- Testing
- Alemtuzumab, Total Body Irradiation, Sirolimus
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Calgary
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant
Nutrition OUtReach In Systems of Healthcare
Many children and adults receiving medical treatments have higher costs, which can make it harder for them to afford groceries. When someone can't afford enough food, and they do not receive proper nutrition it can make treatment…
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant, CAR-T Cell Therapy, Food Insecurity
- Trial name
- NOURISH (NCT06802406)
- Testing
- Food Bags
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- University of Kansas Medical Center
Graft Vs Host Disease, Coping Skills
Horizons Chronic Graft-Versus-Host-Disease Study
This research is being done to evaluate the feasibility of the Horizons Program, a group-based behavioral intervention, to enhance quality of life in patients with chronic graft-versus-host disease.
- Conditions
- Graft Vs Host Disease, Coping Skills, Quality of Life, Stem Cell Transplant Complications
- Trial name
- NCT06160986
- Testing
- Horizons Group Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Miami
Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid)
Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
A first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation…
- Conditions
- Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic
- Trial name
- ThINKK-01 (NCT07518654)
- Testing
- Therapeutic Inducers of Natural Killer Killing (ThINKK)
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Michel Duval
Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO)
Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy, and lung injury affects as many as 25% of children receiving HSCT.
- Trial name
- HSCT (NCT04908735)
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati